Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5144)
All Articles published online
|
Publishing Process of This Article
|
Mar 6, 2024 (publication date) through Mar 21, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wu D, Wang Q, Yan S, Sun X, Qin Y, Yuan M, Wang NY, Huang XT. Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports. World J Clin Cases 2024; 12(7): 1296-1304 [PMID: 38524525 DOI: 10.12998/wjcc.v12.i7.1296] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Wu D, Wang Q, Yan S, Sun X, Qin Y, Yuan M, Wang NY, Huang XT. Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports. World J Clin Cases 2024; 12(7): 1296-1304 [PMID: 38524525 DOI: 10.12998/wjcc.v12.i7.1296] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v12/i7/1296.htm |
| Number | Citing Articles |
| 1 |
Guanglun Ping, Guoyong Cai, Ying Wei, Xiangli Mo, Li Liu, Wencui Zhu, Yi Zhang. Knockdown of Lymphoid Enhancer-binding Factor 1 Inhibits Pancreatic Adenocarcinoma Growth and Neoangiogenesis by Curbing Notch1 and Nuclear Factor Kappa B Signaling Pathways. Pancreas 2026; 55(4): e397 doi: 10.1097/MPA.0000000000002562
|
| 2 |
Shihao Zhao, Wenhui Wang, Jingyi Li, Zhigang Li, Zhanbo Liu, Shunchao Zhang, Zhaoqi Chen, Hongling Wang, Xiangqi Wang, Juntao Wang. Clinical research progress of fruquintinib in the treatment of malignant tumors. Investigational New Drugs 2024; 42(6): 612 doi: 10.1007/s10637-024-01476-6
|